Search All News
Dr. Aaron Viny, MD MS, has been awarded the R37 MERIT grant by the National Cancer Institute for his research on mutations in the gene Stag2, frequently found in various types of cancers.
Carlos Romero was diagnosed with leukemia when he was in eighth grade. With his sister as the donor for his third stem cell transplant, Carlos is now fully in remission.
After being diagnosed in 2001 with chronic lymphocytic leukemia and again in 2018 with lung cancer, Mary Ann is now successfully managing her disease and returning to her calling as an actress.
The new Walkers Scholar Fellowship for MDS research has been made possible by a generous gift from Nancy and Joe Walker.
- February 28, 2023
Tannishtha Reya, PhD, is establishing the new Irving Cancer Drug Discovery Program, devoted to helping faculty accelerate research discoveries in their labs to the clinic.
- December 19, 2022
Exciting new clinical investigations, including results of the ALPINE study, show promising, more effective treatment for patients with CLL.
- November 10, 2022
In the last 50 years, the main approaches for treating myelodysplastic syndromes or acute myeloid leukemia have not changed. The Kousteni lab aims to change that.
- August 10, 2022
Columbia Cancer congratulates Drs. Catherine Spina and Aaron Viny, recipients of a prestigious Clinical Scientist Development Award by the Doris Duke Charitable Foundation.
- April 22, 2021
HICCC researchers have combined a systems biology approach with machine learning to identify a new risk stratification for patients with pediatric acute myeloid leukemia (AML).
- January 26, 2021
Congratulations to Dr. Aaron Viny for receiving a 2021 prestigious Scholar Award from the American Society of Hematology.
- August 13, 2020
Columbia University’s Division of Hematology and Oncology welcomes new members, Andrew Lipsky, MD, and Aaron Viny, MD, MS, both assistant professors of medicine, to the leukemia group.
- June 23, 2020
Adolfo Ferrando has been awarded the William Dameshek Prize for his contributions in advancing acute lymphoblastic leukemia (ALL) and T-cell acute lymphoblastic leukemia (T-ALL) research.